Clinical Trials Logo
  1. Home
  2. Obsessive-Compulsive Disorder
  3. NCT01933919

A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder

Obsessive Compulsive Disorder Clinical Trial

Official title:
A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder

Clinical Trial Summary

The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item from baseline to the last observation visit (10 weeks) in pediatric/adolescent participants with obsessive compulsive disorder (OCD).

The objective of the second phase of the study is to evaluate the long-term safety and efficacy of fluvoxamine in pediatric/adolescent patients with OCD.

Clinical Trial Description

The first phase will be conducted in a randomized, placebo-controlled, double-blind manner to evaluate the efficacy of fluvoxamine on change from baseline to the last observation visit in the JCY-BOCS 10-item total score. Eligible patients will be allocated to the fluvoxamine group or placebo group in a 1:1 ratio using the experience of fluvoxamine treatment and age as stratification factors (dynamic allocation). The first phase consists of a screening period of 1-2 weeks, a forced titration dose period of 2 weeks, a dose adjustment period of 4 weeks, a maintained dose period of 4 weeks, and a tapering dose period of 0-4 weeks.

The 2nd phase will be conducted in an open-label manner in participants who completed the first phase to evaluate the long-term safety of fluvoxamine. The 2nd phase consists of 3 periods; a forced titration dose period of 2 weeks, a flexible dose period of 50 weeks, and a tapering dose period of 0-4 weeks. After the last dose of study drug (including tapering dose period) or the early termination visit, participants will be followed for up to 30 days. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01933919
Study type Interventional
Source AbbVie
Contact
Status Completed
Phase Phase 3
Start date August 14, 2013
Completion date July 1, 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Completed NCT02855580 - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Completed NCT02229903 - An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD N/A
Completed NCT02202915 - CBT for Pediatric OCD: Community Training Pilot N/A
Completed NCT01794156 - Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder N/A
Completed NCT02089984 - Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders N/A
Completed NCT01348529 - Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT00965211 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome N/A
Completed NCT01172873 - D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD N/A
Completed NCT00723060 - Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Phase 4
Not yet recruiting NCT00743834 - Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Phase 4
Completed NCT02421315 - Overlapping Neural Circuits in Pediatric OCD N/A
Completed NCT02194075 - Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Phase 4
Completed NCT01981317 - Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder N/A
Completed NCT01686087 - Attaining and Maintaining Wellness in Obsessive-compulsive Disorder N/A
Terminated NCT00997087 - A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder Phase 2
Completed NCT01331876 - Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy N/A
Completed NCT00533806 - Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder Phase 3
Completed NCT00517244 - Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders N/A
Completed NCT00169377 - Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD) Phase 1/Phase 2